BioCryst Pharmaceuticals
Quick facts
| Founded | 1986 |
|---|
Phase 3 pipeline
- BCX7353 capsules · Immunology / Rare Disease
BCX7353 is a selective inhibitor of plasma kallikrein that reduces bradykinin generation in the contact system pathway.
Phase 2 pipeline
- BCX4161 · Immunology
BCX4161 is a small molecule inhibitor of the C1 inhibitor of the complement system. - BCX4208 · Immunology
BCX4208 is a PNP (purine nucleoside phosphorylase) inhibitor that increases deoxyadenosine levels to selectively expand T-regulatory cells and suppress autoreactive immune responses. - BCX7353 · Immunology / Rare Disease
BCX7353 is a selective inhibitor of plasma kallikrein that reduces bradykinin generation in the contact system pathway. - forodesine HCl
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about BioCryst Pharmaceuticals
What is BioCryst Pharmaceuticals's pipeline?
BioCryst Pharmaceuticals has 1 drugs in Phase 3, 4 in Phase 2, 5 in Phase 1. Late-stage candidates include BCX7353 capsules.
When was BioCryst Pharmaceuticals founded?
BioCryst Pharmaceuticals was founded in 1986.
Related
- Sector hub: All tracked pharma companies